Evaluation of the Expansion of Newborn screening by additional 28 target diseases - NGS2025

niversitätsklinikum Heidelberg0 sites800,000 target enrollmentJuly 13, 2021

Overview

Phase: N/A
Intervention: Not specified
Conditions: Not specified
Sponsor: niversitätsklinikum Heidelberg
Enrollment: 800000
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 13, 2021

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

niversitätsklinikum Heidelberg

Eligibility Criteria

Inclusion Criteria

•Newborn in the catchment area of the Newborn screening laboratory Heidelberg ( Newborn which will get a regular screen at the newborn screening laboratory)
•Written consent of at least one parent or caregiver

Exclusion Criteria

•No informed consent
•sample doesnt provide the sufficient amount of material for the analysis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

N/A

Establishment of expanded newborn screening system in Tokyo metropolitaSpiral Muscular Atrophy, Severe Combinede Immunodeficiency, Pompe Disease, Mucopolysaccharidosis type I &ampII, Fabry disease

JPRN-UMIN000048900Department of Pediatrics, The Jikei University School of Medicine4,000

Completed

N/A

Research on newborn screening for treatable neonatal and childhood diseasesprimary immunodeficiency, spinal muscular atrophy

JPRN-UMIN000045633Tokyo Medical and Dental University

Recruiting

N/A

establishing newborn screening program for metabolic disorders in Udupi DistrictHealth Condition 1: null- all newborns 48 hours old also includes,doctors nurses anganwadi workers

CTRI/2017/09/009912Vision Group Science and Technology

Recruiting

N/A

Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3Familial Hemophagocytic Lymphohistiocytosis 2/3

DRKS00028493niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)im Zentrum für Translationale Zellforschung200

Not Yet Recruiting

N/A

Software based affordable screening for newborns and young childre

CTRI/2022/11/047688Algorithmic Biologics Private Limited